ルキソリチニブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ルキソリチニブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

9nih.gov

4^th place

24^th place

8doi.org

2^nd place

6^th place

3nejm.org

2,374^th place

2,486^th place

1medscape.com

719^th place

3,311^th place

1mixonline.jp

low place

4,576^th place

1delawareonline.com

4,565^th place

low place

1asco.org

low place

1web.archive.org

1^st place

1ovid.com

low place

1pmda.go.jp

6,690^th place

394^th place

1cancerit.jp

low place

8,165^th place

1novartis.co.jp

low place

9,532^nd place

asco.org

chicago2011.asco.org

ASCO Annual Meeting 2011: JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis Archived 2011年11月21日, at the Wayback Machine.

cancerit.jp

『ルキソリチニブリンのFDA承認』（プレスリリース）。http://www.cancerit.jp/17384.html。2014年9月3日閲覧。

delawareonline.com

Natoli, Cori Anne (May 5, 2012), “Incyte looks to ride on drug's success”, The News Journal May 6, 2012閲覧。

doi.org

Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter (2012). “Ruxolitinib”. Nature Reviews Drug Discovery 11 (2): 103–4. doi:10.1038/nrd3652. PMID 22293561.
Harrison, C; Mesa, R; Ross, D; Mead, A; Keohane, C; Gotlib, J; Verstovsek, S (2013). “Practical management of patients with myelofibrosis receiving ruxolitinib”. Expert Review of Hematology 6 (5): 511–23. doi:10.1586/17474086.2013.827413. PMID 24083419.
Xing, Luzhou et al (2014). “Letter, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition”. Nature Medicine. doi:10.1038/nm.3645. Advance online publication retrieved 17 August 2014
“JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis”. N. Engl. J. Med. 366 (9): 787–98. (March 2012). doi:10.1056/NEJMoa1110556. PMID 22375970.
“A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis”. N. Engl. J. Med. 366 (9): 799–807. (March 2012). doi:10.1056/NEJMoa1110557. PMC 4822164. PMID 22375971.
“Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms”. N. Engl. J. Med. 366 (9): 844–6. (March 2012). doi:10.1056/NEJMe1115119. PMID 22375977.
“Targeting myeloproliferative neoplasms with JAK inhibitors”. Curr. Opin. Hematol. 18 (2): 105–10. (March 2011). doi:10.1097/MOH.0b013e3283439964. PMID 21245760.
Wysham, NG; Allada G; Sullivan DR (2013). “An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.”. Chest 143 (5): 1478–9. doi:10.1378/chest.12-1604. PMID 23648912.

medscape.com

reference.medscape.com

“Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. 16 February 2014閲覧。

mixonline.jp

“医療用薬６製品　新効能などを追加承認”. ミクス (2015年9月28日). 2015年9月28日閲覧。

nejm.org

nih.gov

pubmed.ncbi.nlm.nih.gov

Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter (2012). “Ruxolitinib”. Nature Reviews Drug Discovery 11 (2): 103–4. doi:10.1038/nrd3652. PMID 22293561.
Harrison, C; Mesa, R; Ross, D; Mead, A; Keohane, C; Gotlib, J; Verstovsek, S (2013). “Practical management of patients with myelofibrosis receiving ruxolitinib”. Expert Review of Hematology 6 (5): 511–23. doi:10.1586/17474086.2013.827413. PMID 24083419.
“JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis”. N. Engl. J. Med. 366 (9): 787–98. (March 2012). doi:10.1056/NEJMoa1110556. PMID 22375970.
“A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis”. N. Engl. J. Med. 366 (9): 799–807. (March 2012). doi:10.1056/NEJMoa1110557. PMC 4822164. PMID 22375971.
“Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms”. N. Engl. J. Med. 366 (9): 844–6. (March 2012). doi:10.1056/NEJMe1115119. PMID 22375977.
“Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis”. IDrugs 13 (6): 394–403. (June 2010). PMID 20506062.
“Targeting myeloproliferative neoplasms with JAK inhibitors”. Curr. Opin. Hematol. 18 (2): 105–10. (March 2011). doi:10.1097/MOH.0b013e3283439964. PMID 21245760.
Wysham, NG; Allada G; Sullivan DR (2013). “An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.”. Chest 143 (5): 1478–9. doi:10.1378/chest.12-1604. PMID 23648912.

pmc.ncbi.nlm.nih.gov

“A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis”. N. Engl. J. Med. 366 (9): 799–807. (March 2012). doi:10.1056/NEJMoa1110557. PMC 4822164. PMID 22375971.

novartis.co.jp

『ノバルティスのルキソリチニブ、骨髄線維症の治療薬としてEUにおける承認勧告をCHMPから取得』（プレスリリース）。2014年9月3日閲覧。

ovid.com

Insights.ovid.com

“Targeting myeloproliferative neoplasms with JAK inhibitors”. Curr. Opin. Hematol. 18 (2): 105–10. (March 2011). doi:10.1097/MOH.0b013e3283439964. PMID 21245760.

pmda.go.jp

info.pmda.go.jp

“ジャカビ錠5mg 添付文書” (2015年9月). 2016年7月3日閲覧。

web.archive.org

ASCO Annual Meeting 2011: JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis Archived 2011年11月21日, at the Wayback Machine.